Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.it

NTC grants Chinoin the license and distribution rights in Mexico and LatAm for…

The deal represents an important step for the internationalization of such product that was developed to respond to the unmet medical needs to enhance patient compliance. The deal represents an important step for the internationalization of such product that was developed to respond to the unmet medical needs to enhance patient compliance. In fact, bowel preparation before a colonoscopy is currently often experienced as burdensome and, if inadequately performed, it leads to suboptimal...

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and…

Mini Oral Presentation DetailsTitle: The A2AR Antagonist Inupadenant Promotes Humoral Responses in Patients Abstract Number: 174MO Session Title: Mini Oral Session 1 Date / Time: December 12, 2024 at 9:24 am CESTTitle: Inupadenant Combined with Chemotherapy in Patients with Non-Squamous NSCLC Progressing On or After Immune Checkpoint Inhibitor Therapy: Results from Dose-Finding Part of the A2A-005 Trial Abstract Number: 120MO Session Title: Mini Oral Session 2 Date / Time: December 12,...

Curaleaf Report: Online and unregulated cannabis poses serious health risks with…

This is largely being driven by consumers buying illegal cannabis to seek relief from health conditions like chronic pain, insomnia, and anxiety (73% of online purchasers) - many of whom could be eligible for legally prescribed medical cannabis. This is largely being driven by consumers buying illegal cannabis to seek relief from health conditions like chronic pain, insomnia, and anxiety (73% of online purchasers) - many of whom could be eligible for legally prescribed medical cannabis...

Meiyume Debuts at Cosmopack Asia 2024: "Elevate: Reaching New Heights in Beauty…

Elevating Towards a Sustainable FutureSustainability is core to Meiyume's operations. At Cosmopack, visitors can explore eco-friendly packaging materials and achievements in green manufacturing processes. Meiyume's latest sustainable achievements will be highlighted, including a Cosmotalks panel on 12th November, titled "Look Beyond the Label: Consumer Expectations for Sustainable Beauty," where Meiyume will share insights on how sustainability, technology, and data are reshaping the…

Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD

CTAD Lifetime Achievement Award October 29, 4:20 p.m. to 4:55 p.m. (CET) CTAD Lifetime Achievement Award October 29,4:20 p.m. to 4:55 p.m. (CET) Late Breaking Symposium 1 – The AHEAD 3-45 Study: Design and Results of a Novel Screening Process for a Preclinical AD Trial From6:10 to 6:50 p.m. (CET)onOctober 29(Tuesday). This late breaking symposium will present the design of the AHEAD 3-45 trial focused on lecanemab in pre-clinical Alzheimer's disease and the findings on use...

Indivior Announces Q3 2024 Financial Results

Webcast link: https://edge.media-server.com/mmc/p/ppm4ske8Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BId4d5b45a6f3e4291ba42150c1620fc64(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration) Webcast link:https://edge.media-server.com/mmc/p/ppm4ske8Participants may access the presentation...

ONWARD® Medical Successfully Raises EUR 50 Million in an Upsized Capital…

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Ottobock, a global leader in the fields of prosthetics, orthotics and exoskeleton technology, acquires c.10% of ONWARD Medical N.V.'s share capital and initiates strategic relationshipCash runway extended to two years or moreCapital increase was upsized to EUR 50M on the basis of strong demand from high-quality long-only and sector specialist...

Essity: Interim Report, Quarter 3, 2024

CEO'S COMMENTS CEO'S COMMENTS The third quarter was characterized by strong earnings with profitable growth and record-high cash flow. Our focus on growth resulted in higher volumes and increased market shares all over the world. Volume growth and higher market shares Every day Essity cares for the hygiene and health of a billion people across 150 countries. Our solutions are needed regardless of the economic situation and we are working to constantly increase the value of...

J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of…

Mutations in the epidermal growth factor receptor (EGFR) is a key driver in the pathogenesis of NSCLC, with 3rd Generation EGFR-TKIs like osimertinib serving as the cornerstone of treatment. Unfortunately, eventually resistance to this treatment will occur, leading to cancer relapse and disease progression. JIN-A02, developed by J INTS BIO, is the 4th-generation EGFR-TKI specifically designed to address this. By targeting both the original mutations and those acquired subsequently as a result of…

Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer…

Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and indicated by the FDA 1 Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBCRibociclib (Kisqali) is also the only Category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with...

Pharming Group reports third quarter 2024 financial results and provides…

Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja® revenue growthRUCONEST® third quarter revenue increased by 6% to US$63.6 million, compared to the third quarter 2023Joenja® (leniolisib) third quarter revenue increased by 72% to US$11.2 million, compared to the third quarter 2023 First nine months total revenues increased by 25% to US$204.5 million, compared...

PolTREG launches Phase 2 cell therapy trial in children with presymptomatic…

Treating diabetes patients earlier with PTG-007 could provide functional cureRecruitment will go ahead after European Medicines Agency approvalCompany has 12 years' worth of safety and efficacy data for PTG-007 Gdańsk, Poland – 24 October 2024 (07:00 CET)– PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a wide range of autoimmune diseases, has launched a placebo-controlled Phase 2 clinical...

J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in…

Ovarian cancer remains one of the most aggressive and lethal gynecological malignancies, with approximately 70% of patients diagnosed at an advanced stage. While many patients initially respond to standard chemotherapy, drug resistance eventually develops, leading to disease progression and cancer relapse. JIN-001 was designed to address this issue and by targeting heat shock protein 90 (HSP90), a molecular chaperone that plays a crucial role in enabling cancer cells to adapt to therapeutic…

Casio to Release MR-G Inspired by the Brilliant Gleam of Japanese Katana Swords

The distinctive shock-resistant MRG-B2000JS design is based on the Juryoku-Maru: San motif, evoking its extraordinary shape and expressing the traditional techniques and aesthetics unique to Japanese katana swords. The recrystallized hybrid titanium bezel with its unique temper pattern is made in layers of Ti64 and pure titanium that are subjected to high-temperature, high-pressure compression. This material is then cut, polished, and recrystallized to replicate the beautiful blade pattern of…

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a…

The mean non-menstrual pelvic pain score was reduced by 50% The mean non-menstrual pelvic pain score was reduced by 50% Most of the patients reported normal menstrual periods No typical peri-menopausal symptoms were reported There were no significant changes in bone mineral density or key sex hormone levels About 190 million women worldwide suffer from endometriosis, making up a market size of$200 billion SHANGHAI , Oct. 24, 2024 /PRNewswire/ -- Hope Medicine...

Anti-CD38 mAb Market to Accelerate Substantially During the Study Period…

Key Takeaways from the Anti-CD38 mAb Market Report Key Takeaways from the Anti-CD38 mAb Market Report Discover which therapies are expected to grab the anti-CD38 mAb market share @Anti-CD38 mAb Market Report Anti-CD38 mAb Market Dynamics The market for anti-CD38 mAbs has undergone significant growth and transformation in recent years, driven primarily by theincreasing prevalence of multiple myelomaand the d emand for more effective treatment options. The market...

NTC grants Chinoin the license and distribution rights in Mexico and LatAm for…

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and…

Curaleaf Report: Online and unregulated cannabis poses serious health risks with…

ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance…

Final Day of Global Health Exhibition Celebrates the Next Generation of Health…

Seegene Holds Partner Executive Roundtable with Microsoft, and Springer Nature…

Vistin Pharma ASA: Invitation to Q3 2024 conference call

Dedicare's Interim Report 1 January - 30 September 2024: Market still…

Orexo Interim Report Q3 2024

Sobi Q3 2024 report: Strong growth and significant pipeline momentum

Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a…

Meiyume Debuts at Cosmopack Asia 2024: "Elevate: Reaching New Heights in Beauty…

Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD

Indivior Announces Q3 2024 Financial Results

ONWARD® Medical Successfully Raises EUR 50 Million in an Upsized Capital…

Essity: Interim Report, Quarter 3, 2024

J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of…

Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer…

Pharming Group reports third quarter 2024 financial results and provides…

PolTREG launches Phase 2 cell therapy trial in children with presymptomatic…

J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in…

Casio to Release MR-G Inspired by the Brilliant Gleam of Japanese Katana Swords

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a…

Anti-CD38 mAb Market to Accelerate Substantially During the Study Period…